<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
0002-6145-11
</NDCCode>
<PackageDescription>
1 TUBE in 1 CARTON (0002-6145-11) / 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) / 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01)
</PackageDescription>
<NDC11Code>
00002-6145-11
</NDC11Code>
<ProductNDC>
0002-6145
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Baqsimi
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Glucagon
</NonProprietaryName>
<DosageFormName>
POWDER
</DosageFormName>
<RouteName>
NASAL
</RouteName>
<StartMarketingDate>
20190724
</StartMarketingDate>
<EndMarketingDate>
20250823
</EndMarketingDate>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA210134
</ApplicationNumber>
<LabelerName>
Eli Lilly and Company
</LabelerName>
<SubstanceName>
GLUCAGON
</SubstanceName>
<StrengthNumber>
3
</StrengthNumber>
<StrengthUnit>
mg/1
</StrengthUnit>
<Pharm_Classes>
Antihypoglycemic Agent [EPC], Decreased GI Motility [PE], Decreased GI Smooth Muscle Tone [PE], Decreased Glycolysis [PE], Gastrointestinal Motility Inhibitor [EPC], Increased Gluconeogenesis [PE], Increased Glycogenolysis [PE]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2025-08-25
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough/>
<StartMarketingDatePackage>
20190806
</StartMarketingDatePackage>
<EndMarketingDatePackage>
20250823
</EndMarketingDatePackage>
<SamplePackage>
N
</SamplePackage>
</NDC>